The Netherlands Is Losing Its AgriTech Edge — Here's What's at Stake

Jan de Vries · 2026-10-30

The Netherlands has built a reputation as Europe's agricultural powerhouse. Think cutting-edge greenhouses, world-class seed breeders, and a food production system other countries study and try to copy. But a new report from Invest-NL, the Dutch national investment institution, suggests that reputation might be running on borrowed time. The report, called *Deep Dive Agrifood Biotech*, doesn't mince words. It argues that the Netherlands is falling behind as other countries move faster to turn lab breakthroughs into actual products on shelves and in fields. And the numbers attached to that warning are hard to ignore. ### The Money on the Table If the Netherlands tackled the barriers facing its agrifood biotech companies, Invest-NL estimates it could unlock roughly $18 billion in extra annual revenue by 2040. That's not pocket change. But without coordinated action on regulation, financing, and commercialization, much of that upside could end up captured by competitors elsewhere. The study draws on interviews with more than 150 entrepreneurs, investors, researchers, and policymakers, plus investment data stretching from 2010 through April 2026. It zeroes in on three areas: seed breeding and genetics, biological agricultural inputs, and biotech-derived food ingredients. ### Great at Starting, Struggling to Scale Here's the imbalance that jumped out at me. The Netherlands accounts for 3.3% of biotech startups worldwide — but only 1.3% of scale-ups. That gap, based on broader biotech data cited from TNO (the Netherlands Organisation for Applied Scientific Research), tells a story. The country is excellent at generating innovation. It's far less successful at helping young companies grow into serious commercial players. Invest-NL keeps running into the same three weaknesses: - Too few promising technologies turn into scalable ventures - Regulatory and validation processes slow down market entry - Not enough financing to get companies to industrial production In a favorable scenario, annual Dutch agrifood biotech revenues could hit about $27 billion by 2040. Under current conditions? More like $8.7 billion to $9.8 billion. That's a staggering difference. One important nuance: the report doesn't say the Netherlands needs to manufacture everything at home. Instead, it should hold onto the strategically valuable stuff — knowledge, intellectual property, companies, specialized capabilities — while leaning on European production networks where that makes sense. ### Ten Years to Say Yes Perhaps the most striking obstacle involves biological crop protection, where Dutch companies are developing alternatives to conventional chemical pesticides. Getting European regulatory approval for a new biological crop protection product can take eight to ten years. The existing frameworks were mostly built around chemical products, so they fit biological innovations poorly. > "Innovation is not the issue. Turning it into businesses at scale is." As a result, some companies launch first in markets like Brazil and the United States, where commercialization moves faster. Invest-NL warns that Europe could lose ground in a biological crop protection market that might expand seven- to tenfold by 2040. Food biotech runs into similar walls. Approval for novel ingredients can take one to three years longer in Europe than in the U.S., and building a first commercial production facility can cost tens or even hundreds of millions of dollars. For fermentation-derived food ingredients alone, favorable conditions could support roughly $8.7 billion in annual Dutch revenues by 2040 — versus about $2.2 billion under existing policies. The report is careful to say faster approvals shouldn't come at the expense of safety. Instead, regulators should offer earlier guidance, more predictable assessments, and chances for companies to validate products under real-world conditions. That's the kind of middle ground that could keep the Netherlands in the game — before the crown quietly changes hands.